Cellusion has been selected Tokyo metropolitan government R&D facility support grant 2019.

TOKYO (SEPTEMBER 12, 2019)-, Cellusion Inc. (Headquarters, Tokyo; CEO: Shin Hatou, M.D., Ph.D., “Cellusion”) announced Tokyo metropolitan government has selected Cellusion for R&D facility support grant 2019. With this support, Cellusion is planning to open a new laboratory in Tokyo. Cellusion will accelerate to deliver novel regenerative therapy for all bullous keratopathy patients.

See details; http://www.senryaku.metro.tokyo.jp/news/2019/201906_002.html

For further information: please ask us through contact form in our website.

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Company ： Cellusion Inc.
CEO ： Shin Hatou, M.D., Ph.D.
Headquarter ：2-4-15 Minamiaoyama, Minato, Tokyo 107-0062, JAPAN
Founded ： January 2015
URL ： https://cellusion.jp/en/